Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Liabilities (2016 - 2026)

Ironwood Pharmaceuticals' Total Liabilities history spans 17 years, with the latest figure at $658.7 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 1.0% to $658.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $658.7 million, a 1.0% increase, with the full-year FY2025 number at $658.7 million, up 1.0% from a year prior.
  • Total Liabilities hit $658.7 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $660.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for IRWD hit a ceiling of $950.0 million in Q2 2023 and a floor of $442.8 million in Q2 2022.
  • Historically, Total Liabilities has averaged $605.2 million across 5 years, with a median of $608.4 million in 2022.
  • Biggest five-year swings in Total Liabilities: soared 114.54% in 2023 and later decreased 24.49% in 2024.
  • Tracing IRWD's Total Liabilities over 5 years: stood at $521.0 million in 2021, then dropped by 13.99% to $448.1 million in 2022, then grew by 5.79% to $474.1 million in 2023, then skyrocketed by 37.57% to $652.2 million in 2024, then rose by 1.0% to $658.7 million in 2025.
  • Business Quant data shows Total Liabilities for IRWD at $658.7 million in Q4 2025, $660.2 million in Q3 2025, and $651.1 million in Q2 2025.